GRAIL (NASDAQ:GRAL) CFO Sells 23,619 Shares of Company Stock

GRAIL, Inc. (NASDAQ:GRAL) CFO Aaron Freidin sold 23,619 shares of the business’s stock in a transaction on Monday, October 5th. The stock was sold at an average price of $146.39, for a total transaction of $3,457,585.41. Following the completion of the sale, the chief financial officer directly owned 225,364 shares of the company’s stock, valued at approximately $32,991,035.96. The trade was a 9.49% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Aaron Freidin also recently made the following trade(s):

• On Monday, September 21st, Aaron Freidin sold 4,100 shares of GRAIL stock. The stock was sold at an average price of $93.34, for a total transaction of $382,694.00.
• On Thursday, August 27th, Aaron Freidin sold 7,900 shares of GRAIL stock. The shares were sold at an average price of $85.01, for a total transaction of $671,579.00.

GRAIL Stock Down 3.2%

Shares of NASDAQ GRAL traded down $4.38 during trading on Wednesday, hitting $132.90. The company had a trading volume of 992,328 shares, compared to its average volume of 980,656. The stock has a fifty day simple moving average of $88.31 and a two-hundred day simple moving average of $70.39. GRAIL, Inc. has a fifty-two week low of $41.50 and a fifty-two week high of $166.48. The firm has a market capitalization of $5.94 billion, a price-to-earnings ratio of -13.63 and a beta of 2.83.

GRAIL (NASDAQ:GRAL) last released its earnings results on Wednesday, August 5th. The company reported ($2.56) EPS for the quarter, topping analysts’ consensus estimates of ($2.66) by $0.10. GRAIL had a negative net margin of 236.95% and a negative return on equity of 15.88%. The business had revenue of $44.69 million during the quarter, compared to analysts’ expectations of $42.39 million. On average, analysts anticipate that GRAIL, Inc. will post -10.41 earnings per share for the current year.

Institutional Trading of GRAIL

A number of hedge funds have recently bought and sold shares of GRAL. Fifth Third Bancorp raised its holdings in GRAIL by 15,733.3% in the 1st quarter. Fifth Third Bancorp now owns 475 shares of the company’s stock valued at $25,000 after acquiring an additional 472 shares during the last quarter. Caitong International Asset Management Co. Ltd acquired a new position in shares of GRAIL during the 4th quarter worth approximately $28,000. Geneos Wealth Management Inc. grew its position in shares of GRAIL by 160.0% in the first quarter. Geneos Wealth Management Inc. now owns 585 shares of the company’s stock valued at $30,000 after purchasing an additional 360 shares in the last quarter. Allworth Financial LP purchased a new stake in shares of GRAIL in the second quarter valued at approximately $35,000. Finally, Osbon Capital Management LLC acquired a new stake in shares of GRAIL in the fourth quarter valued at approximately $51,000.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on GRAL. Weiss Ratings reissued a “sell (d-)” rating on shares of GRAIL in a report on Friday, July 17th. UBS Group lifted their price target on GRAIL from $105.00 to $175.00 and gave the stock a “buy” rating in a research note on Friday, October 2nd. Robert W. Baird boosted their price target on GRAIL from $96.00 to $118.00 and gave the stock an “outperform” rating in a research report on Tuesday, September 22nd. TD Cowen reissued a “buy” rating on shares of GRAIL in a research note on Thursday, September 24th. Finally, Canaccord Genuity Group raised their price objective on GRAIL from $80.00 to $150.00 and gave the company a “buy” rating in a report on Monday, September 28th. Five investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, GRAIL currently has an average rating of “Hold” and an average target price of $102.70.

About GRAIL

GRAIL, Inc is a healthcare company focused on developing blood-based technologies for the early detection of cancer. Its goal is to identify cancer signals before symptoms appear, when treatment may be more effective, by applying genomics, machine learning and other analytical methods to blood samples.

The company’s primary product is the Galleri multi-cancer early detection test, a prescription laboratory-developed test designed to screen for signals associated with multiple types of cancer from a single blood draw.